Dignitana AB engages in the development, manufacture and marketing of medical technology systems related to medical cooling. The company is headquartered in Lund, Skane and currently employs 25 full-time employees. The company develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The firm focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. The company has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Follow-Up Questions
DIZTF の株価パフォーマンスは？
DIZTF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Dignitana AB の主な事業テーマや業界は？
Dignitana AB は Health Care 業界、セクターは Health Care に属しています。
